ess-2 Antibody

What is ESS2 and what are its known biological functions?

ESS2 (Essential Spliceosomal Factor 2, also known as DGCR14) functions primarily as a transcriptional coregulator with multiple biological roles. Research indicates that ESS2:

• Acts as a transcriptional coregulator in CD4+ T cells, influencing post-thymic T-cell survival

• Shows high expression in normal prostate tissue and is significantly upregulated in prostate cancer

• Enhances transcriptional activities of multiple transcription factors, including c-Myc and SMAD2/3

• Regulates TGF-β signaling and expression of TGF-β target genes

• Is located in a chromosomal region associated with 22q11.2 deletion syndrome, which causes heart defects, skeletal abnormalities, and immunodeficiency

Complete knockout of ESS2 in mice results in embryonic lethality, underscoring its essential role in development .

What are the recommended methods for detecting ESS2 in experimental samples?

Several techniques have been successfully employed to detect ESS2 in research settings:

• Western blotting: Effectively used to detect ESS2 protein in various cell lines including LNCaP, DU145, PC3, and HEK293

• Immunofluorescence staining: Provides visualization of ESS2 subcellular localization, particularly in prostate cancer cell lines such as DU145 and PC3

• Immunohistochemistry: Successfully applied for ESS2 detection in formalin-fixed paraffin-embedded human prostate tissues

• qRT-PCR: Used for quantifying ESS2 mRNA expression levels in both tissues and cell lines

When selecting an ESS2 antibody, researchers should consider the specific epitope recognized and validate the antibody for their particular application and experimental system.

How can I validate the specificity of an ESS2 antibody?

Rigorous validation is essential for obtaining reliable research results with ESS2 antibodies:

• Positive controls: Use cell lines with high ESS2 expression, such as HEK293, PC3, DU145, and LNCaP

• Negative controls: Compare with ESS2 knockdown or knockout samples (e.g., using shRNA as demonstrated in published studies)

• Multiple detection methods: Cross-validate findings using different techniques (western blot, immunofluorescence, immunohistochemistry)

• Recombination verification: For genetic models, confirm deletion of the ESS2 allele using PCR detection (e.g., 152-bp fragment in CD4-specific ESS2 knockout mice)

• Expression correlation: Verify expected pattern of expression (e.g., higher expression in prostate cancer vs. normal prostate tissue)

Studies have successfully validated ESS2 antibodies through comparison of staining patterns in control versus ESS2-depleted cells, demonstrating the importance of proper controls.

What is the expression pattern of ESS2 in normal and disease tissues?

ESS2 exhibits distinct expression patterns across different tissues and disease states:

This expression pattern suggests ESS2 as a potential biomarker for prostate cancer and a key regulator in specific immune cell populations.

How does ESS2 contribute to T-cell development and function?

Research using CD4-specific ESS2 knockout mice has revealed critical roles in T-cell biology:

• ESS2 is essential for post-thymic T-cell survival through the Myc and IL-7 signaling pathways

• CD4-specific ESS2 knockout mice (ESS2^ΔCD4/ΔCD4^) show:

  • Reduced naïve T-cell numbers in the spleen while thymocyte numbers remain unchanged

  • Decreased NKT cells in both thymus and spleen

  • Increased γδT cells in thymus and spleen

  • Altered expression of Myc target genes and oxidative phosphorylation pathway genes

  • Impaired maintenance of T-cell survival in response to IL-7

These findings indicate that ESS2 plays a critical role in regulating T-cell homeostasis and may have implications for understanding immunodeficiency disorders.

What methodological approaches are recommended for studying ESS2-dependent transcriptional regulation?

ESS2 functions as a transcriptional coregulator, requiring specialized methods to study its mechanisms:

• Genome-wide expression analysis: RNA-seq has successfully identified ESS2-regulated genes in CD4 single-positive thymocytes

• ChIP assays: Can be employed to study ESS2 recruitment to specific genomic loci and interactions with transcription factors

• Transcriptional activity assays: Luciferase reporter systems have been used to demonstrate ESS2 enhancement of c-Myc and SMAD2/3 transcriptional activities

• Co-localization studies: Immunofluorescence microscopy to analyze nuclear co-localization of ESS2 with transcription factors like c-Myc

• Bioinformatic analyses: GSEA and DAVID pathway analyses have identified Myc target genes and oxidative phosphorylation pathways as significantly altered in ESS2-deficient cells

These complementary approaches provide a comprehensive understanding of ESS2's role in transcriptional regulation across different cellular contexts.

How can ESS2 antibodies be used to investigate its role in prostate cancer progression?

ESS2 antibodies are valuable tools for exploring its function in prostate cancer:

• Expression profiling: Quantify ESS2 protein levels across prostate cancer progression stages using immunohistochemistry

• Target gene regulation: Investigate ESS2's role in regulating specific genes (IER3, LIF, CSF2) that show significant correlation with ESS2 expression in prostate cancer patients

• Mechanistic studies: Examine ESS2's interaction with CHD1, as ESS2 depletion selectively suppresses CHD1 function

• TGF-β pathway analysis: Study ESS2's regulation of TGF-β expression and TGF-β target genes (e.g., MMP-9) that promote tumor invasion

• Epithelial-mesenchymal transition (EMT): Investigate ESS2's role in EMT, as TGF-β promotes EMT via the SMAD2/3 pathway, which is enhanced by ESS2

Research has shown that ESS2 mRNA levels are significantly upregulated in prostate cancer tissues compared to normal prostate (12.8 × 10⁻⁵ vs. 2.39 × 10⁻⁵), making it a potentially important biomarker and therapeutic target for castration-resistant prostate cancer .

What are the key considerations when designing ESS2 knockout or knockdown experiments?

When manipulating ESS2 expression experimentally, researchers should consider:

• Embryonic lethality: Complete ESS2 knockout is embryonically lethal in mice, necessitating conditional knockout approaches

• Cell-type specificity: Tissue-specific knockouts (e.g., CD4-specific ESS2 knockout) allow investigation of ESS2 function in specific contexts

• Verification methods: Confirm knockdown/knockout efficiency at both mRNA and protein levels using appropriate primers and ESS2 antibodies

• Phenotype characterization: For immune studies, analyze multiple T-cell subpopulations (CD4+, CD8+, NKT, γδT) as ESS2 affects them differently

• Pathway analysis: Assess effects on known ESS2-regulated pathways including Myc, IL-7, and TGF-β signaling

Research shows that CD4-specific ESS2 knockout mice (ESS2^ΔCD4/ΔCD4^) can be generated using the Cre/loxP system, with efficient deletion confirmed by PCR detection of a 152-bp fragment and significantly reduced ESS2 mRNA expression in target cells .

How can bioinformatic approaches complement ESS2 antibody-based research?

Bioinformatic analyses provide valuable context for ESS2 antibody studies:

• Expression correlation analysis: The R2 Genomics Analysis platform has revealed positive correlations between ESS2 expression and T-cell-related genes in hepatitis C virus patients, mixed lymphoma, and Crohn's disease

• Pathway enrichment: GSEA and DAVID analyses identified immune pathways and Myc target genes altered in ESS2-deficient cells

• Clinical significance assessment: ESS2 expression correlates with several genes (LDHA, RACK1, CDK4) in immunodeficient patients

• Target gene identification: Bioinformatic approaches have identified CHD1 target genes (IER3, LIF, CSF2) significantly correlated with ESS2 expression in prostate cancer patients

These computational approaches can guide hypothesis generation and experimental design for antibody-based validation studies.

What methodologies are recommended for studying ESS2 protein-protein interactions?

To investigate ESS2's interactions with other proteins:

• Co-immunoprecipitation: Use ESS2 antibodies to pull down ESS2 and identify interacting partners by immunoblotting or mass spectrometry

• Proximity ligation assay: Detect and visualize protein interactions in situ with high sensitivity

• Transcriptional activity assays: Measure the effect of ESS2 on the transcriptional activity of potential interacting partners (as demonstrated with c-Myc and SMAD2/3)

• ChIP-reChIP: Investigate co-occupancy of ESS2 with other transcription factors at specific genomic loci

Research has identified several important ESS2 interaction partners to investigate:

• c-Myc: ESS2 enhances c-Myc transcriptional activity and co-localizes with c-Myc in the nucleus

• CHD1: ESS2 depletion selectively suppresses CHD1 function

• SMAD2/3: ESS2 significantly enhances SMAD2/3 transcriptional activities in the TGF-β pathway

How can ESS2 antibodies be used in translational research for immunodeficiency disorders?

ESS2's role in T-cell development makes it relevant for immunodeficiency research:

• Association with 22q11.2 deletion syndrome: ESS2 is located in a chromosomal region linked to this syndrome which causes immunodeficiency

• Correlation studies: ESS2 expression correlates with multiple immune-related genes in patients with hepatitis C virus, mixed lymphoma, and Crohn's disease

• T-cell subset analysis: ESS2 antibodies can be used to analyze correlation between ESS2 expression and T-cell subset distributions in patient samples

• Mechanistic investigation: Study how ESS2 influences survival of naïve T cells through Myc and IL-7 signaling pathways

• Biomarker potential: Assess ESS2 as a potential biomarker for T-cell related disorders

Gene expression analysis has shown that several T-cell-related genes identified by GSEA have significant positive correlations with ESS2 expression in lymphocytes from patients with various immune disorders .

What are the considerations when optimizing ESS2 antibody-based immunofluorescence experiments?

For successful immunofluorescence detection of ESS2:

• Fixation optimization: Different fixation protocols may affect epitope accessibility and detection sensitivity

• Permeabilization conditions: Optimize to ensure antibody access to nuclear ESS2 while preserving cellular architecture

• Antibody dilution: Titrate primary ESS2 antibody to achieve optimal signal-to-noise ratio

• Co-staining markers: Include markers for subcellular compartments to confirm ESS2 localization (particularly nuclear co-localization with transcription factors)

• Microscopy parameters: Use confocal microscopy for detailed localization studies, especially when examining co-localization

Immunofluorescence staining has successfully shown that ESS2 protein is highly expressed in androgen-independent prostate cancer cell lines (DU145 and PC3) and co-localizes with c-Myc in the nucleus .

How do methodological approaches differ when studying ESS2 in different tissue contexts?

Research approaches must be adapted for different tissue types and research questions:

• Prostate cancer tissues: Formalin-fixed paraffin-embedded (FFPE) samples require optimized antigen retrieval methods for immunohistochemistry

• T-cell studies: Flow cytometry analysis with specific markers (CD3, CD4, CD8, CD62L) is essential for identifying different T-cell subpopulations affected by ESS2

• Cell lines: Different lysis buffers may be optimal for different cell types when preparing samples for western blotting

• Bone metastasis models: Special considerations for studying ESS2 in PC3 cells, which are derived from bone metastasis and show characteristics of small cell neuroendocrine carcinoma

• Primary T-cell cultures: Protocols for studying IL-7 response in naïve CD4+ T cells require specific culture conditions

Each tissue context presents unique challenges and requires optimization of experimental protocols for reliable ESS2 detection and functional studies.

What methodological approaches can integrate ESS2 antibody-based detection with functional assays?

Combining detection with functional assays provides deeper mechanistic insights:

• Knockdown-rescue experiments: Deplete endogenous ESS2 and express tagged versions for functional rescue and mechanistic studies

• Inducible expression systems: Control ESS2 expression temporally to study immediate versus long-term effects

• Live-cell imaging: Track ESS2 dynamics in response to stimuli when using fluorescently tagged constructs

• Signaling pathway activation: Monitor changes in ESS2 localization or expression in response to pathway activation (e.g., TGF-β stimulation)

• Gene expression correlation: Combine ESS2 expression data with target gene expression analyses

Research has demonstrated that TGF-β-dependent MMP-9 mRNA induction is significantly lower in ESS2-knockdown cells, illustrating how ESS2 detection can be integrated with functional analyses of target gene expression .

How can I troubleshoot weak or non-specific signals when using ESS2 antibodies?

When encountering issues with ESS2 antibody performance:

• Antibody concentration: Titrate to determine optimal concentration for your specific application

• Blocking optimization: Test different blocking agents (BSA, milk, commercial blockers) to reduce background

• Antigen retrieval (for IHC): Optimize pH and heating methods for maximum epitope exposure

• Positive controls: Include samples known to express high levels of ESS2 (e.g., PC3, DU145, HEK293 cells)

• Negative controls: Include ESS2 knockdown samples using validated shRNA constructs

• Detection system sensitivity: Consider enhanced chemiluminescence for western blots or tyramide signal amplification for IHC/IF when detecting low abundance targets

Research demonstrates successful ESS2 detection in multiple systems, suggesting that with proper optimization, ESS2 antibodies can provide specific and reliable results across various experimental platforms.